Iradier

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iradier

Iradier is a fixed-dose combination product containing synthetic hormones, classified as a Hormonal Contraceptive for Systemic Use. It is available by prescription only (Rx) as an Oral Tablet (pill) and is an established generic equivalent of popular brand formulations.

Quick Facts: Iradier Entity

Property Description
Active ingredients Drospirenone (DRSP) and Ethinyl Estradiol (EE)
Form Oral Tablet (Pill)
Pharmacological class Progestogens and Estrogens, Fixed Combinations
Common use Prevention of pregnancy (Contraception)
Origin Synthetic steroid derivatives

Defining the Combination and Class

Iradier's classification places it within the ATC group G03AA: Progestogens and Estrogens, Fixed Combinations. This synthetic medicine contains a blend of two distinct types of hormones: the progestin Drospirenone and the estrogen Ethinyl Estradiol. This composition is frequently utilized by women of reproductive age seeking systemic, non-permanent birth control.

Composition: Unique Features and Differentiation

The core differentiation of Iradier lies in its progestin component, Drospirenone. This synthetic molecule is derived from a structure related to spironolactone. Pharmacological studies indicate that Drospirenone is clinically recognized for possessing anti-mineralocorticoid activity in addition to its primary progestational effects. This property helps oppose the effects of other hormones that can lead to fluid retention, a characteristic often sought by patients.

General Purpose

The primary therapeutic purpose of the Iradier medicinal entity is the prevention of pregnancy in women of reproductive potential. This function is achieved by the systemic intervention of the combined synthetic hormones, which prevent the biological events necessary for conception. This biological mechanism supports the reliable efficacy of the medication for its intended purpose of fertility management.

Regulatory References

  1. NIH DailyMed

What side effects are possible with Iradier?

Iradier, a combination of Drospirenone and Ethinyl Estradiol, has a safety profile defined by documented adverse reactions and specific regulatory constraints detailed in official prescribing information.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their frequency as observed in clinical trials, primarily affecting the nervous, reproductive, and psychiatric systems. Very Common reactions (occurring in 10% or more of patients) include headache or migraine and breast pain/discomfort. Common reactions (occurring in 1% to 10%) include nausea, depression, abdominal pain, and a decrease in libido.

Serious Safety Concerns

The most serious documented concerns relate to vascular health. Combined oral contraceptives, including this formulation, are associated with a risk of Venous Thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolic Events (ATE). The risk of these events is highest during the first year of use or upon restarting therapy after a break.

The unique anti-mineralocorticoid activity of Drospirenone introduces a specific risk of Hyperkalemia (high serum potassium levels). This condition warrants specific monitoring and leads directly to contraindications in certain populations.

Safety Constraints and Special Populations

Official labeling defines strict safety constraints:

  • Contraindications: Use is strictly forbidden for women with pre-existing renal impairment, hepatic impairment, or adrenal insufficiency due to the hyperkalemia risk, and for smokers aged 35 years or older due to severe cardiovascular risk.
  • Procedural Restrictions: The medication must be discontinued before and after major surgery to reduce the risk of thrombosis.
  • Interactions: The product is contraindicated with specific Hepatitis C drug combinations due to the potential for significant liver enzyme elevation.

Overdose and Emergency Response

The official regulatory documentation for Iradier, a combination of Drospirenone and Ethinyl Estradiol, defines specific expected outcomes and required actions in case of overdose. Documented clinical manifestations of acute overexposure primarily affect the gastrointestinal and reproductive systems, and typically include nausea, vomiting, and withdrawal bleeding (vaginal bleeding) which may occur hours to days following the ingestion of excess hormonal content.

While an acute overdose of this oral contraceptive is generally not expected to be life-threatening, the unique component Drospirenone carries a specific physiological risk. Due to its anti-mineralocorticoid activity, the potential for hyperkalemia (elevated potassium levels) is a crucial consideration. This risk is specifically heightened in patients with pre-existing conditions such as renal, hepatic, or adrenal insufficiency, requiring specialized attention.

Regulators mandate immediate action for any suspected overexposure. It is required to seek immediate medical attention and contact a Poison Control Center for guidance. Since no specific antidote is known, management is strictly limited to symptomatic and supportive treatment. This includes necessary monitoring of the patient's fluid and electrolyte balance, with a specific focus on checking serum potassium concentration.

Therapeutic Uses of Iradier

What Iradier Treats: Main Uses and Benefits

The primary therapeutic benefit of Iradier, a combination oral contraceptive, is to provide a reliable, non-permanent method for the prevention of pregnancy for women of reproductive potential. This systemic therapy is also utilized for the symptomatic management of certain distressing, hormonally-influenced conditions, generally in patients who choose an oral contraceptive method.

The core therapeutic domains addressed are contraception, the management of symptoms linked to Premenstrual Dysphoric Disorder (PMDD), and the supportive relief of moderate acne vulgaris.

Management and Relief

The medication is commonly used to help address symptom clusters that may become intense or disruptive that characterize PMDD. It supports the management of pronounced symptoms like intense mood swings, irritability, and anxiety that interfere with daily functioning, and may assist with symptomatic support for daily stability during difficult episodes. Iradier contributes to improved comfort across two additional domains: it is applied for the supportive relief of moderate acne vulgaris, and due to its properties, generally contributes to easing the overall symptom load related to fluid retention and generalized bloating.

“The therapeutic approach supports patients during episodes of heightened discomfort by providing supportive relief when symptoms interfere with routine activities.”


Quick Fact: Relief for Cyclic Discomfort

Symptom Focus Therapeutic Benefit
Severe Mood Swings Helps manage emotional symptoms of PMDD.
Fluid Retention Contributes to easing generalized bloating and swelling.
Moderate Acne Applied for supportive relief of hormonally-influenced skin manifestations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Iradier?

Iradier, a combination hormonal contraceptive (Drospirenone/Ethinyl Estradiol), is approved for use in post-menarcheal females of reproductive potential for pregnancy prevention, and conditionally for PMDD and moderate acne. Eligibility is strictly governed by regulatory classifications based on cardiovascular and metabolic risk factors.


Contraindicated Populations

Use of Iradier is contraindicated (prohibited) in females with specific, high-risk conditions. These include a current or history of thrombotic disorders (such as deep vein thrombosis or stroke), uncontrolled hypertension, diabetes with vascular involvement, and migraine with aura. Due to its components, it is also contraindicated in females with renal insufficiency, adrenal insufficiency, or severe liver disease. Females over 35 who smoke must not use this medicine. It is also contraindicated during known or suspected pregnancy.


Eligibility Restrictions

Use is not recommended in the immediate postpartum period (first 4 weeks) or while breastfeeding. The medicine is not indicated for use in pre-menarcheal females or post-menopausal women. Caution is required for patients taking concurrent medications that increase serum potassium, due to the anti-mineralocorticoid activity of Drospirenone.

What should I know about interactions with other medicines?

The interaction profile for Iradier (Drospirenone/Ethinyl Estradiol) is governed by specific regulatory constraints concerning co-administered substances. The co-administration of Iradier with drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, is formally classified as a contraindicated combination due to the officially documented risk of elevated liver enzymes.

The profile highlights clinically significant pharmacokinetic interactions related to the CYP3A4 enzyme system. Co-administration with strong CYP3A4 inducers (such as certain anticonvulsants) may lead to a decrease in the hormonal component concentrations, which increases the regulatory risk of reduced contraceptive effectiveness. Conversely, strong CYP3A4 inhibitors (like certain antifungals) may increase the plasma concentration of Drospirenone.

A key pharmacodynamic interaction arises from Drospirenone’s anti-mineralocorticoid activity. Concurrent use with other medications that increase serum potassium (e.g., ACE inhibitors, NSAIDs, potassium-sparing diuretics) is officially documented to carry a risk of hyperkalemia. This risk is specified as being heightened and requiring serum potassium concentration monitoring during the initial treatment cycle for patients with pre-existing conditions that predispose to high potassium (such as renal or adrenal insufficiency). Additionally, the Ethinyl Estradiol component may increase the plasma concentration of co-administered drugs whose clearance is inhibited by oral contraceptives, such as Cyclosporine or Caffeine.

Mechanism of Action

Central Endocrine Suppression

The primary mechanism involves the combined agonism of Ethinyl Estradiol and Drospirenone at the Estrogen and Progesterone Receptors ( ER/PR) within the pituitary gland and hypothalamus. This interaction initiates a strong negative feedback signal, resulting in the central suppression of the Hypothalamic-Pituitary-Ovarian (HPO) axis. This mechanistic cascade suppresses the release of FSH and LH, which is the core physiological consequence of the central suppression.

Peripheral Barrier and Tissue Modulation

In addition to the central action, the progestin component modifies reproductive tissue physiology. This involves causing a significant increase in mucus viscosity in the cervix that alters sperm transit. Simultaneously, the hormones alter the endometrial lining, modifying its structure to make the tissue unreceptive. These peripheral effects lead to multiple, distinct physiological alterations in the reproductive tract.

Unique Mineralocorticoid Receptor Modulation

Drospirenone provides a distinct secondary action through its antagonism at the Mineralocorticoid Receptor ( MR), particularly in the renal tubules. This targets the RAAS pathway, leading to antagonism of the Mineralocorticoid Receptor-mediated effects. This mechanism leads to modulation of systemic fluid and electrolyte balance.

Dosage and Administration Information

How Iradier is Used: General Administration Guidelines

Iradier, a combination product containing Drospirenone (3 mg) and Ethinyl Estradiol (0.02 mg), is used according to a fixed, cyclic administration schedule.


Administration Scope

Feature Standard Instruction
Route of Administration The medication is taken orally (by mouth).
Dosing Schedule The standard dose is one tablet daily, administered as a 28-day course.
Timing in Relation to Meals Tablets may be taken without regard to meals, and are often suggested for administration after the evening meal or at bedtime.
Age-Group Rules Use for moderate acne is specified for women who have achieved menarche and are at least 14 years of age.

Procedural Consistency and Timing

Iradier is administered as a cyclic regimen composed of 24 active tablets followed immediately by 4 inert tablets. Daily adherence is required, and the tablet must be taken at the same time every day to maintain the intended hormone level.

Procedural constraints dictate that administration must follow the order directed on the blister pack. Furthermore, the initial administration requires the use of a non-hormonal back-up method of contraception for the first 7 consecutive days of the first cycle. If the medication is used for the management of Premenstrual Dysphoric Disorder (PMDD) symptoms, the clinical evaluation of its effectiveness has been limited to a duration of three menstrual cycles.

Special Procedural Notes

Instances of severe vomiting or diarrhea occurring within 3 to 4 hours of taking an active tablet must be treated as a missed dose. Due to the Drospirenone component’s anti-mineralocorticoid activity, clinical guidelines specify that serum potassium concentration should be checked during the first cycle for women on long-term potassium-increasing medications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Iradier

Evidence for Use in Pregnancy Prevention (Contraception)

Research examined this medicine through large-scale studies applied in research contexts involving women of reproductive age. The core research scenario involved observing responses over defined time intervals to understand patterns related to the occurrence of pregnancy, which was calculated using the Pearl Index (a standard measurement). Findings describe patterns observed in the studies where the occurrence of pregnancy was monitored when the product was used consistently. Long-term effects are not fully established for every aspect of use, though post-marketing surveillance continues to contribute to the broader evidence landscape.


Evidence for Use in Premenstrual Dysphoric Disorder (PMDD)

For PMDD, the research strategy involved randomized, double-blind, placebo-controlled trials (RCTs). These studies explored how symptoms change over time, specifically examining outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed where women using the product reported lower average symptom scores compared to the placebo group. Research highlights the change in measured scores during the study period. Follow-up durations were limited (typically three to seven cycles), and certainty remains low regarding the consistency of reported findings over several years.


Evidence for Use in Moderate Acne Vulgaris

The evidence comes from randomized, double-blind, placebo-controlled trials applied in research contexts involving young women who were enrolled for oral contraception. Studies monitored outcomes reflecting daily functioning, specifically measuring the reduction in various types of acne lesions. Studies reported measured changes in lesion counts in the study group compared to the placebo group. The core research results apply only to the populations studied: females with moderate facial acne who were enrolled for contraception. Evidence is limited for long-term outcomes, as most core studies monitored responses for only six cycles.


What is Still Uncertain About the Research Base

Several research limitations are noted. For both PMDD and acne, follow-up durations were limited, meaning that the long-term effects are not fully established regarding the maintenance of observed changes over many years. The results apply only to the populations studied, and data for certain groups, such as women with comorbidities or those with symptom severity outside the moderate range, remain insufficient.

Key Studies & References

  1. Drospirenone and Ethinyl Estradiol (NIH DailyMed) - General Drug Information and Uses

Frequently Asked Questions (FAQ)

Common questions about Iradier (FAQ)


Q: What is Iradier officially approved to treat?

A: According to official regulatory documents, this medicine is approved for three specific indications. It is used to prevent pregnancy (contraception), to treat the symptoms of Premenstrual Dysphoric Disorder (PMDD), and to treat moderate acne vulgaris in women who have started menstruation.


Q: Is Iradier a long-term treatment or is it usually taken for a short time?

A: According to the official product information, Iradier is typically prescribed for ongoing, continuous use. It is administered on a 28-day cyclic schedule for as long as contraception or treatment for the approved condition is desired. This type of hormonal medicine is not generally intended for short-term courses.


Q: What is the expected timeline to notice the benefits of Iradier?

A: For contraception, a non-hormonal back-up method is recommended for the first 7 consecutive days to help establish the contraceptive effect. The onset of effect for chronic conditions like acne and PMDD is measured over multiple treatment cycles.


Q: Is the full effect of Iradier felt immediately or does it build up over time?

A: The contraceptive effect requires a minimum of 7 days to take hold. For conditions like acne and PMDD, clinical trials indicate that the full measured effectiveness for these chronic conditions was observed after several months, typically three to six treatment cycles.


Q: Does Iradier cause weight gain or weight loss?

A: Weight gain is listed as a common side effect reported in clinical trials. Official regulatory documents also note that weight loss has been reported as an uncommon adverse reaction.


Q: Is hair loss a reported side effect of Iradier?

A: Yes, the official post-marketing experience reports that alopecia (hair loss) is listed as an adverse reaction.


Q: Does Iradier affect sleep patterns or cause insomnia?

A: Insomnia, or difficulty sleeping, is listed as an uncommon psychiatric adverse reaction reported in clinical trials. Additionally, sleep problems may be reported as a symptom in patients who experience the common side effect of depression.


Q: What should I do if I experience a mild side effect from Iradier?

A: The official patient information describes that continuing the medication is generally suggested for mild, temporary effects like spotting or nausea in the first few months. The product label advises that a healthcare provider should be contacted if the problem persists or gets worse.


Q: Is it true that Iradier can cause severe allergic reactions?

A: Official documentation reports the possibility of severe allergic-type reactions. Symptoms of this can include angioedema, which is swelling of the face, tongue, or throat. Symptoms like this are considered medical emergencies and require immediate medical attention.


Q: Can I take Iradier with common over-the-counter pain relievers?

A: Regulatory documents indicate that caution is required with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) if they are taken long-term and daily, as they can increase serum potassium. This interaction is a caution noted in the regulatory documents, and potassium monitoring may be part of the medical management. For other common, occasional OTC pain relievers, official product information does not note a specific restriction.


Q: Are there any specific foods or beverages to avoid while taking Iradier?

A: Official patient information indicates that consuming grapefruit or grapefruit juice is advised against while using this medicine. This restriction is necessary because consuming grapefruit can potentially change how the medicine is absorbed in the body.


Q: Does Iradier interact with common vitamins or herbal supplements like St. John's Wort?

A: Official product information indicates that coadministration with the herbal supplement St. John's Wort is officially not recommended. This is because it may decrease the contraceptive hormone levels in the blood, which could lead to reduced effectiveness and increased breakthrough bleeding.


Q: What happens if I miss a dose of Iradier?

A: Instructions for a missed dose vary significantly based on the number of pills missed and which week of the cycle the dose was missed. Missing active tablets increases the risk of pregnancy. The regulatory instructions outline specific procedural steps for managing missed pills, which often include the recommendation to use back-up contraception to reduce the risk of pregnancy.


Q: How soon after missing a dose of Iradier can I take the next one?

A: Official instructions advise that if only one active pill is missed, the recommended action is to take the missed tablet as soon as it is remembered. The next pill should then be taken at the usual time, even if it means taking two pills on the same day.


Q: Can I split or crush Iradier tablets if I have trouble swallowing them?

A: The official patient information states that the tablets must be swallowed whole with liquid. They should not be broken, crushed, or chewed, as this may compromise the intended release or effectiveness of the medicine.


Q: Is Iradier associated with any long-term health risks?

A: Yes, regulatory documents list serious risks associated with use, including an increased risk of Venous and Arterial Thromboembolic Events (blood clots, stroke, and heart attack). Official information indicates that this risk is highest during the first year of use.


Q: What does 'contraindicated' mean in relation to Iradier?

A: The term contraindicated means that a specific condition or factor makes the medication prohibited for use due to a high risk of causing harm. For this drug, contraindications include having a history of blood clots, specific kidney, liver, or adrenal diseases, and smoking while over age 35.


Q: Why might a doctor prescribe Iradier over an older medication?

A: The progestin component of Iradier, drospirenone, has a unique pharmacological feature known as anti-mineralocorticoid activity. This property helps oppose some effects, such as fluid retention, that may be seen with other hormonal contraceptives.


Q: Do many people stop taking Iradier due to side effects?

A: Clinical trial data reports that a percentage of women discontinue use of the medication due to adverse reactions. Menstrual irregularities (bleeding problems) and common issues like nausea or headache are frequently cited as reasons for discontinuation of oral contraceptives.


Q: Why does the packaging for Iradier include a Medication Guide?

A: This medicine is required by the U.S. Food and Drug Administration (FDA) to be dispensed with a Medication Guide. This guide is mandated to help patients understand important instructions and avoid serious adverse events.


Q: Does Iradier contain lactose or gluten for people with sensitivities?

A: According to official product labeling, the active tablets contain lactose monohydrate as a non-medicinal ingredient (excipient). The official package insert must be checked for complete excipient information, including gluten status.


Q: Are there any known occupational hazards associated with Iradier use, like driving?

A: Adverse reactions related to the nervous system, such as dizziness and somnolence (drowsiness), have been reported. These effects may potentially affect the ability to perform tasks requiring alertness, such as operating machinery or driving.


Q: Does Iradier have any black box warnings?

A: Yes, the product carries an FDA-mandated Boxed Warning (often called a Black Box Warning). This warning highlights the increased risk of serious cardiovascular events, including blood clots, heart attack, and stroke, in women who smoke and are over the age of 35.


Q: What pregnancy safety category is Iradier classified under?

A: Iradier is classified as contraindicated (prohibited) for use during known or suspected pregnancy. Regulatory information states that there is no reason to use a hormonal contraceptive when pregnant.


Q: Can children 2 years old use it?

A: Regulatory documents state that this medication is only indicated for use in females who have achieved menarche (the start of menstruation) for its approved indications. It is not indicated for use in pre-menarcheal females.

How should Iradier be stored and disposed of?

Storage Requirements

Iradier tablets must be stored at 25°C (77°F), which is defined as Controlled Room Temperature. The labeling permits brief temperature excursions between 15°C and 30°C (59°F and 86°F).

The medicine must be protected from light, excess heat, and moisture. It is required to keep the tablets in their original container, tightly closed, to maintain stability and prevent degradation. This product does not require refrigeration or special handling beyond adequate room ventilation.

As a mandatory child-safety measure, Iradier must be kept out of the sight and reach of children and pets.

Disposal Instructions

Disposal of any unused or expired Iradier must be managed according to local regulations and official guidance. The preferred disposal method is through a medicine take-back program. The product should not be flushed down the toilet or disposed of in the household trash to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Iradier found in:

A-Z Index: